NCT05105087 · ADVERSE EVENTS

Adverse events

Gynecological Sentinel Lymph Nodes CEUS · Source last updated 2025-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: The PI will follow AEs with start dates occurring any time after informed consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. Events will be followed for outcome information until resolution or stabilization.
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Diagnostic (Perflubutane Microbubble, Ultrasound) Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment. Perflubutane Microbubble: Given subdermally Contrast-Enhanced Ultrasound: Undergo ultrasound	0 / 9	0 / 9	0 / 9

Group identifiers: EG000: Diagnostic (Perflubutane Microbubble, Ultrasound)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
9
description
Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment. Perflubutane Microbubble: Given subdermally Contrast-Enhanced Ultrasound: Undergo ultrasound
id
EG000
other Num Affected
0
other Num At Risk
9
serious Num Affected
0
serious Num At Risk
9
title
Diagnostic (Perflubutane Microbubble, Ultrasound)

frequency Threshold

time Frame

The PI will follow AEs with start dates occurring any time after informed consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. Events will be followed for outcome information until resolution or stabilization.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice